JP2017521374A - 臓器の虚血再灌流傷害を予防するための方法及び組成物 - Google Patents

臓器の虚血再灌流傷害を予防するための方法及び組成物 Download PDF

Info

Publication number
JP2017521374A
JP2017521374A JP2016569875A JP2016569875A JP2017521374A JP 2017521374 A JP2017521374 A JP 2017521374A JP 2016569875 A JP2016569875 A JP 2016569875A JP 2016569875 A JP2016569875 A JP 2016569875A JP 2017521374 A JP2017521374 A JP 2017521374A
Authority
JP
Japan
Prior art keywords
inhibitor
organ
kidney
iri
dialysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016569875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521374A5 (enExample
Inventor
エリザベス シー． スクワイヤース
エリザベス シー． スクワイヤース
シャイ エーリッヒ
シャイ エーリッヒ
ダニエル ローゼンスタイン
ダニエル ローゼンスタイン
ニール シャロン
ニール シャロン
ダニエル ジェイ． オーデンハイマー
ダニエル ジェイ． オーデンハイマー
エレナ フェインスタイン
エレナ フェインスタイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of JP2017521374A publication Critical patent/JP2017521374A/ja
Publication of JP2017521374A5 publication Critical patent/JP2017521374A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016569875A 2014-05-29 2015-05-27 臓器の虚血再灌流傷害を予防するための方法及び組成物 Withdrawn JP2017521374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29
US62/004,239 2014-05-29
PCT/US2015/032499 WO2015183842A1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020074549A Division JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2017521374A true JP2017521374A (ja) 2017-08-03
JP2017521374A5 JP2017521374A5 (enExample) 2018-06-28

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569875A Withdrawn JP2017521374A (ja) 2014-05-29 2015-05-27 臓器の虚血再灌流傷害を予防するための方法及び組成物
JP2020074549A Pending JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020074549A Pending JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Country Status (18)

Country Link
US (3) US20170081665A1 (enExample)
EP (2) EP3149172B1 (enExample)
JP (2) JP2017521374A (enExample)
KR (1) KR20170007492A (enExample)
CN (2) CN112410336A (enExample)
AU (1) AU2015267160B2 (enExample)
BR (1) BR112016028009A2 (enExample)
CA (1) CA2949109A1 (enExample)
DK (2) DK3149172T3 (enExample)
ES (2) ES2862185T3 (enExample)
HU (2) HUE040092T2 (enExample)
IL (2) IL248912A0 (enExample)
LT (2) LT3149172T (enExample)
MX (2) MX373950B (enExample)
PL (2) PL3444349T3 (enExample)
PT (2) PT3444349T (enExample)
SI (2) SI3444349T1 (enExample)
WO (1) WO2015183842A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547274A (ja) * 2020-10-23 2023-11-09 コーズウェイ セラピューティクス リミテッド マイクロｒｎａ－２９の化合物、組成物、および治療法における使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US12091664B2 (en) 2018-01-12 2024-09-17 University Of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
AU2022418939A1 (en) * 2021-12-22 2024-03-21 Na Vaccine Institute Composition for preventing or treating ischemia-reperfusion injury and use thereof
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 一种qpi-1002的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043292A1 (en) * 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO2000044364A2 (en) 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
JP4991547B2 (ja) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
CA2701845A1 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2009155504A2 (en) * 2008-06-20 2009-12-23 The Children's Medical Center Corporation Methods for the modulation of angiogenesis
US8637482B2 (en) * 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
JPWO2011138966A1 (ja) 2010-05-06 2013-07-22 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
US9808461B2 (en) * 2010-11-17 2017-11-07 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
EP2649181B1 (en) 2010-12-06 2016-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043292A1 (en) * 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, VOL.10, SUPP. SUPPL. 4, P.132, ABSTRACT NO. 310, JPN6019014305, ISSN: 0004189242 *
KIDNEY INTERNATIONAL, 2013, VOL.83, PP.404-413, JPN6019014306, ISSN: 0004189243 *
PLOS ONE, 2013, VOL.8, ISSUE 8, E70464, P.1-14, JPN6019014307, ISSN: 0004189244 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547274A (ja) * 2020-10-23 2023-11-09 コーズウェイ セラピューティクス リミテッド マイクロｒｎａ－２９の化合物、組成物、および治療法における使用

Also Published As

Publication number Publication date
PL3149172T3 (pl) 2018-10-31
EP3444349B1 (en) 2021-01-06
HUE040092T2 (hu) 2019-02-28
DK3444349T3 (da) 2021-04-12
AU2015267160B2 (en) 2021-07-29
US9868953B2 (en) 2018-01-16
BR112016028009A2 (pt) 2018-02-20
IL278144A (en) 2020-11-30
PL3444349T3 (pl) 2021-06-28
KR20170007492A (ko) 2017-01-18
SI3149172T1 (sl) 2018-10-30
MX2020005794A (es) 2020-10-28
HUE054226T2 (hu) 2021-08-30
CN112410336A (zh) 2021-02-26
PT3149172T (pt) 2018-10-08
AU2015267160A8 (en) 2016-12-08
CN106661579B (zh) 2020-12-04
LT3444349T (lt) 2021-04-12
WO2015183842A1 (en) 2015-12-03
IL248912A0 (en) 2017-01-31
ES2683869T3 (es) 2018-09-28
DK3149172T3 (en) 2018-08-20
ES2862185T3 (es) 2021-10-07
US20180305696A1 (en) 2018-10-25
MX2016015635A (es) 2017-04-25
AU2015267160A1 (en) 2016-12-01
JP2020128383A (ja) 2020-08-27
CA2949109A1 (en) 2015-12-03
US20170081665A1 (en) 2017-03-23
US20170335327A1 (en) 2017-11-23
CN106661579A (zh) 2017-05-10
EP3444349A1 (en) 2019-02-20
LT3149172T (lt) 2018-09-10
PT3444349T (pt) 2021-04-06
SI3444349T1 (sl) 2021-07-30
MX373950B (es) 2020-07-13
EP3149172A1 (en) 2017-04-05
IL278144B (en) 2021-07-29
EP3149172B1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
JP2020128383A (ja) 臓器の虚血再灌流傷害を予防するための方法及び組成物
US9993567B2 (en) Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
AU2022203170A1 (en) Compositions and methods for inhibiting gene expression of factor Xll
CA3195275A1 (en) In vivo targeting of t cells for mrna therapeutics
TW201920227A (zh) 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物
JP2020500157A (ja) Ｃ３阻害のための組み合わせ治療
WO2009111315A2 (en) Methods for reducing granulomatous inflammation
TWI858005B (zh) 肝毒性之治療
BR112021015323A2 (pt) Moduladores de expressão de malat1
JP2025061882A (ja) Ａｐｏｃ３関連疾患および障害の処置のための方法
US20190060361A1 (en) Methods and compositions relating to regulatory t cells
WO2010065437A1 (en) Modulation of olfml-3 mediated angiogenesis
WO2016180986A1 (en) Mirna compositions for the treatment of mature b-cell neoplasms
TW202430635A (zh) 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法
OA21722A (en) Compositions and methods for inhibiting expression of Prekallikrein (PKK) protein.
EP2673301A2 (en) Frmd4a antagonists and their uses
WO2017147408A1 (en) Methods for the treatment of hematologic cancer
EA049072B1 (ru) КОНСТРУКЦИИ ДЛЯ RNAi, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПОДАВЛЕНИЯ ЭКСПРЕССИИ SCAP, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40014102A (en) Combination therapy for c3 inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200114

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200420